The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Canada-based Kainova Therapeutics has reported positive top line results from the Phase I EPRAD study of DT-9081, an oral EP4 ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Please provide your email address to receive an email when new articles are posted on . The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

Immune checkpoint inhibitors are well known as a form of cancer treatment. Researchers at UZH have now identified a new, important function of these inhibitors: promotion of tissue healing. This ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. "Prices of ...